Acorda Therapeutics manufactures and markets the drugs Inbrija (levodopa inhalation powder) and Ampyra (dalfampridine) in the United States.

[10] Acorda Therapeutics was incorporated in 1995, founded by internist turned entrepreneur Ron Cohen in Hawthorne, New York.

[2] In November 2016, the company announced it was discontinuing development of the drug for post-stroke walking difficulties, after a clinical trial failure.

[14] In the third quarter of 2019, the company's shares dropped by a significant 65.1% as a result of dalfampridine's multiple sclerosis indication facing competition in the United States.

[15][16] In December 2018, the company announced the FDA approval of Inbrija (levodopa inhalation powder) for patients with Parkinson's disease.

This gave the company control over Biote's primary sclerosing cholangitis drug, BTT1023 and the oral adenosine A2A receptor antagonist tozadenant.

[20] In November 2017, the company announced discontinuation of research and development of the Phase III Parkinson's disease drug tozadenant.

[21][22] As of February 14, 2019[update], the members of the board of directors of Acorda Therapeutics were: Ron Cohen, Barry Greene, Peder K. Jensen, John P. Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, and Catherine D.